Research Area HIV Cure

A5341s: Intensive Reservoir Sampling, A5321 Substudy

A5341s: A5321 Sampling Substudy   Longitudinal Sampling Substudy of A5321 is collecting information from measures of different HIV reservoirs, including…

Open and enrolling

See locations

A5354: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas…

Closed to accrual

The duration of the study is up to 72 weeks (a year and a half).

See locations

A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

Studies differences and changes over time in HIV reservoirs (groups of HIV infected cells that ’hide’ from anti-HIV medications).  

Open and enrolling

Participants will be expected to stay in the study for about 7 years.

 

See locations

A5366: Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors

While antiretrovirals known as ARV’s (group of medicines used to treat HIV) have provided very effective treatment of HIV, cure…

Closed to accrual

Up to 9 weeks per participant after a screening period of up to 90 days.

See locations

A5386: N-803 with or without bNAbs for HIV-1 control in participants living with HIV-1 on suppressive ART

Scientists are looking for ways to effectively clear HIV that rests in areas of the body where standard antiretroviral treatment…

Open and enrolling

Maximum of 2 years. Arm A will receive one dose of N-803 at Week 1 and then every 3 weeks for a total of eight doses.

See locations